Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808861 | 0.92 | CCR2 (0.51) | CCR2KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL6807946 | 0.89 | GAA (0.44) | KDM4EPOLBITGB2ICAM1ITGAL | |
| SCHEMBL6807751 | 0.85 | CYP3A4 (0.40) | KDM4EPOLBCALCRL | |
| SCHEMBL6807625 | 0.85 | MEN1 (0.47) | KDM4EPOLBSMN1; SMN2KMT2A | |
| SCHEMBL6808040 | 0.85 | GAA (0.40) | POLBCALCRL | |
| SCHEMBL6803011 | 0.85 | CALCRL (0.52) | ALDH1A1CALCRLCHRM4 | |
| SCHEMBL6807454 | 0.84 | GAA (0.42) | POLBMAPTKMT2A | |
| SCHEMBL6808623 | 0.84 | CYP3A4 (0.42) | KDM4EPOLBITGB2ICAM1ITGAL | |
| SCHEMBL6803451 | 0.82 | CALCRL (0.40) | CALCRL | |
| SCHEMBL6808434 | 0.82 | ITGB2 (0.41) | CCR2POLBITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | CCR2 2521/4885KDM4E 2590/4885BRD4 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.